Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

NCT01402089 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Non Small-cell Lung Cancer
Renal-cell Cancer
Gastrointestinal Stroma Tumor

Interventions

DRUG: Sunitinib
DRUG: Erlotinib
DRUG: Midazolam
DRUG: Caffeine

Sponsor

Markus Joerger

Collaborators

[object Object]